Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.06 +2.3%	$20.81	$13.40 ▼ $25.23	$3.61B	0.64	1.98 million shs	1.47 million shs
ASND Ascendis Pharma A/S	$176.49 +0.4%	$168.04	$111.09 ▼ $183.00	$10.74B	0.38	505,929 shs	465,700 shs
MDCO Medicines	$84.90	$84.90	$17.81 ▼ $84.98	$6.77B	1.1	9.55 million shs	N/A
RDY Dr. Reddy's Laboratories	$14.65 -0.8%	$14.79	$12.26 ▼ $16.89	$12.32B	0.33	1.52 million shs	2.05 million shs
RETA Reata Pharmaceuticals	$172.36	$171.30	$21.83 ▼ $172.46	$6.58B	1.42	1.09 million shs	N/A

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+2.62%	+1.55%	-3.27%	+52.87%	+25.92%
ASND Ascendis Pharma A/S	+4.48%	+1.51%	+1.48%	+22.59%	+28.77%
MDCO Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
RDY Dr. Reddy's Laboratories	-0.14%	-0.81%	-5.66%	+15.73%	-5.06%
RETA Reata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6945 of 5 stars	4.4	3.0	0.0	0.0	3.3	4.2	2.5
ASND Ascendis Pharma A/S	3.5007 of 5 stars	4.5	3.0	0.0	0.0	2.0	1.7	0.6
MDCO Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	3.1732 of 5 stars	2.5	4.0	1.7	0.0	3.2	0.0	1.9
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	26.36% Upside
ASND Ascendis Pharma A/S	3.00	Buy	$220.67	25.03% Upside
MDCO Medicines	0.00	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	15.74% Upside
RETA Reata Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACAD, RETA, MDCO, ASND, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$250.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/13/2025	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$215.00 ➝ $224.00
6/9/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$201.00 ➝ $216.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.85	$0.72 per share	30.60	$4.40 per share	5.01
ASND Ascendis Pharma A/S	$393.54M	27.41	N/A	N/A	($1.88) per share	-93.88
MDCO Medicines	$6.14M	1,102.36	N/A	N/A	($0.30) per share	-283.00
RDY Dr. Reddy's Laboratories	$3.81B	3.21	$1.02 per share	14.29	$4.73 per share	3.10
RETA Reata Pharmaceuticals	$23.48M	280.05	N/A	N/A	($1.79) per share	-96.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.10	29.03	4.65	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	735.38	N/A	-93.22%	N/A	-33.29%	9/2/2025 (Estimated)
MDCO Medicines	-$123.16M	-$2.91	N/A	N/A	N/A	N/A	N/A	-25.70%	N/A
RDY Dr. Reddy's Laboratories	$663M	$0.66	22.19	17.86	5.22	17.38%	17.98%	12.24%	7/25/2025 (Estimated)
RETA Reata Pharmaceuticals	-$311.90M	N/A	0.00	N/A	N/A	N/A	-922.50%	-73.39%	N/A

Latest ACAD, RETA, MDCO, ASND, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
7/25/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.19	N/A	N/A	N/A	$88.27 billion	N/A
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
MDCO Medicines	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.08	0.55%	N/A	12.12%	N/A
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ASND Ascendis Pharma A/S	N/A	1.04	0.71
MDCO Medicines	21.45	0.77	0.77
RDY Dr. Reddy's Laboratories	0.02	1.92	1.37
RETA Reata Pharmaceuticals	0.84	3.21	3.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ASND Ascendis Pharma A/S	N/A
MDCO Medicines	N/A
RDY Dr. Reddy's Laboratories	3.85%
RETA Reata Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ASND Ascendis Pharma A/S	40.00%
MDCO Medicines	8.41%
RDY Dr. Reddy's Laboratories	2.00%
RETA Reata Pharmaceuticals	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ASND Ascendis Pharma A/S	1,017	61.13 million	36.68 million	Optionable
MDCO Medicines	62	79.72 million	N/A	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable
RETA Reata Pharmaceuticals	321	38.15 million	27.93 million	Optionable

ACAD, RETA, MDCO, ASND, and RDY Headlines

Recent News About These Companies

Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects

February 12, 2025 | fiercebiotech.comF

Arbe Robotics (NASDAQ:ARBE) Stock Quotes, Forecast and News Summary

November 1, 2024 | benzinga.com

What to Know: How Israel Could Retaliate Against Iran

October 27, 2024 | nytimes.com

Reta Hendrickson

September 11, 2024 | newsandsentinel.comN

Reata rockets on data for Nrf2 drug reacquired from AbbVie

August 8, 2024 | pharmaphorum.comP

Lazard hires veteran healthcare dealmaker Colocci as vice chairman

May 9, 2024 | investing.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 18, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 16, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 11, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 9, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 4, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 2, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 28, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 26, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 21, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 19, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 14, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 12, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 7, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 5, 2024 | accesswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Growth Stocks Too Small for Institutions to Buy
By Gabriel Osorio-Mazilli | June 19, 2025
View 3 Growth Stocks Too Small for Institutions to Buy
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
On Holding: The Athleisure Stock Analysts Say Could Jump 40%
By Gabriel Osorio-Mazilli | July 8, 2025
View On Holding: The Athleisure Stock Analysts Say Could Jump 40%
Dollar Tree Stock Hits a Pivotal Point, Can It Continue?
By Gabriel Osorio-Mazilli | June 27, 2025
View Dollar Tree Stock Hits a Pivotal Point, Can It Continue?

ACAD, RETA, MDCO, ASND, and RDY Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.06 +0.49 (+2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$22.26 +0.21 (+0.93%)

As of 07:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S NASDAQ:ASND

$176.49 +0.78 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$176.40 -0.09 (-0.05%)

As of 04:16 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Medicines NASDAQ:MDCO

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Dr. Reddy's Laboratories NYSE:RDY

$14.64 -0.12 (-0.78%)

Closing price 03:59 PM Eastern

Extended Trading

$14.68 +0.04 (+0.27%)

As of 06:26 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time